Update (June 25, 2026): Glucocorticoid vs Oclacitinib Comparative Pruritus Control in Canine Atopic Dermatitis

Bottom line.

• In a blinded, randomized clinical trial of 226 client-owned dogs with chronic atopic dermatitis comparing oclacitinib with ciclosporin, owner-assessed pruritus VAS reductions were significantly greater in the oclacitinib group at all time points up to day 28 (day 1: 25.6% vs 6.5%; P < 0.05); by day 84, both agents converged to comparable efficacy (61.0% vs 61.5%).¹
• At day 14, the percentage reduction from baseline CADESI-02 was significantly greater in the oclacitinib group (58.7%) than in the ciclosporin group (43.0%); oclacitinib passed noninferiority testing for CADESI-02 at day 28, demonstrating comparable lesion control at the primary endpoint.¹
• Three times as many adverse events attributed to gastrointestinal signs were reported in the ciclosporin group compared with the oclacitinib group; oclacitinib-treated dogs showed none of the acute glucocorticoid-class effects (polyuria, polydipsia, panting, polyphagia) seen in systemic steroid comparisons.¹
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts (comparators)

• Oclacitinib (Apoquel): Selective oral JAK1 inhibitor; 0.4–0.6 mg/kg twice daily for 14 days, then once daily in the key trials; rapid onset (hours to days).¹
• Ciclosporin (Atopica): Oral calcineurin inhibitor; once daily in the key trial; slower onset (4–6 weeks for full effect).¹
• Glucocorticoids: Oral prednisolone/methylprednisolone; rapid onset but associated with well-documented steroid-class adverse events on long-term use; referenced here as the historical standard against which oclacitinib is contextualized.²
• Indication discussed here: Comparative pruritus and skin lesion control in canine atopic dermatitis.¹

Trying to choose between pruritus control options for an atopic dog?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Oclacitinib vs ciclosporin head-to-head RCT (Little et al. 2015)

A total of 226 client-owned dogs with a history of atopic dermatitis from eight sites were enrolled in a blinded, randomized clinical trial incorporating a noninferiority test at day 28.¹ Dogs received oral oclacitinib (0.4–0.6 mg/kg twice daily for 14 days, then once daily) or oral ciclosporin (3.2–6.6 mg/kg once daily) for 12 weeks. Owners assessed pruritus using an enhanced visual analog scale (VAS), and veterinarians assessed dermatitis using the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-02.

On days 1, 2, 7, 14, 28, 56 and 84, the percentage reduction from baseline for owner-assessed pruritus changed from 25.6 to 61.0% in the oclacitinib group compared with 6.5 to 61.5% in the ciclosporin group; differences were significant at all time points up to day 28.¹ By day 84, both agents had converged to essentially identical pruritus control. At day 14, percentage reduction in CADESI-02 was significantly greater in the oclacitinib group (58.7%) than the ciclosporin group (43.0%).¹ Oclacitinib passed the prespecified noninferiority test for CADESI-02 at day 28. Three times as many gastrointestinal adverse events were attributed to ciclosporin compared with oclacitinib.

Safety profile contrast with systemic glucocorticoids

Systemic glucocorticoids produce rapid pruritus control but carry well-documented class effects with long-term use: polyuria, polydipsia, panting, polyphagia, increased susceptibility to infection, and iatrogenic hyperadrenocorticism. In the pivotal oclacitinib field trials (Cosgrove et al. 2013), the acute glucocorticoid-type side effects (polyuria, polydipsia, panting, polyphagia) were seen in fewer than 2% of oclacitinib-treated dogs at standard doses, and oclacitinib does not suppress the hypothalamic-pituitary-adrenal (HPA) axis.² This distinguishes oclacitinib from systemic steroids for long-term pruritus management.

Clinical implications of the onset difference

The key clinical implication of the oclacitinib-vs-ciclosporin comparison is the onset gap: oclacitinib provides meaningful pruritus relief within 1–2 days, while ciclosporin requires 4–6 weeks for full effect. This gap justifies the evidence-based practice of co-initiating a short bridge course of prednisolone (or using oclacitinib itself as the induction agent) when ciclosporin is chosen for long-term management. The ICADA 2015 guidelines acknowledge both as effective for chronic AD without specifying a preferred agent, supporting individualized treatment decisions based on patient factors, owner preferences and access.³

How this fits clinical practice

For a dog presenting with acute moderate-to-severe pruritus, oclacitinib's rapid onset makes it the preferred pharmacological intervention when immediate pruritus relief is the priority. For a dog requiring long-term maintenance therapy, the convergence of oclacitinib and ciclosporin by 8–12 weeks allows selection based on cost, owner compliance with injection (lokivetmab) vs oral medication, and individual tolerability profiles. Systemic glucocorticoids remain appropriate for short-term flare control and are the most cost-accessible option globally, but are not recommended as first-line long-term monotherapy given the class adverse effect profile. Do not infer specific doses from this summary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. 2015. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 26(1):23-30. https://onlinelibrary.wiley.com/doi/abs/10.1111/vde.12186
2. Cosgrove SB, Wren JA, Cleaver DM, et al. 2013. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 24(5):479-e114. https://onlinelibrary.wiley.com/doi/full/10.1111/vde.12047
3. Olivry T, DeBoer DJ, Favrot C, et al.; International Committee on Allergic Diseases of Animals. 2015. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11:210. https://pubmed.ncbi.nlm.nih.gov/26276051/

Changelog

• 2026-06-25: First published.